Coya Therapeutics Announces Leadership Changes and New Director

Coya Therapeutics, Inc. ( (COYA) ) just unveiled an update.

Coya Therapeutics, Inc. is a Houston-based, clinical-stage biotechnology company focused on developing proprietary treatments that leverage regulatory T cells to address systemic inflammation and neuroinflammation. Its pipeline includes Treg-enhancing biologics, Treg-derived exosomes and autologous Treg cell therapies, with lead candidate COYA 302 being evaluated for amyotrophic lateral sclerosis and other neurodegenerative diseases.

On March 29, 2026, founder Howard Berman, Ph.D., resigned from Coya’s board and his role as Executive Chairman, effective April 1, 2026, as a planned step following the CEO transition begun in November 2024. In connection with his departure, he entered a separation agreement providing a prorated 2026 bonus, extended health coverage and continued vesting and exercise flexibility for stock options, while releasing claims and reaffirming confidentiality and non-disparagement commitments.

Also effective April 1, 2026, the board appointed veteran pharma and biotech executive Mark H. Pavao as an independent Class III director to fill the vacancy, granting him options to purchase 10,000 shares under the company’s equity plan and standard non-employee director compensation. The board and management emphasized that Pavao’s three decades of commercialization experience, particularly in neuroscience, are expected to support Coya’s progression from a clinical-stage developer toward potential commercialization of COYA 302 and other neuroinflammation-focused therapies.

The most recent analyst rating on (COYA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Spark’s Take on COYA Stock

According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.

The score is held back primarily by persistent losses and ongoing cash burn, alongside weak technical trend signals (below major moving averages with negative MACD). Offsetting factors include a debt-free balance sheet with improved equity and positive corporate developments supporting liquidity and clinical progress.

To see Spark’s full report on COYA stock, click here.

More about Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a Houston-based, clinical-stage biotechnology company focused on developing proprietary treatments that leverage regulatory T cells to address systemic inflammation and neuroinflammation. Its pipeline includes Treg-enhancing biologics, Treg-derived exosomes and autologous Treg cell therapies, with lead candidate COYA 302 being evaluated for amyotrophic lateral sclerosis and other neurodegenerative diseases.

On March 29, 2026, founder Howard Berman, Ph.D., resigned from Coya’s board and his role as Executive Chairman, effective April 1, 2026, as a planned step following the CEO transition begun in November 2024. In connection with his departure, he entered a separation agreement providing a prorated 2026 bonus, extended health coverage and continued vesting and exercise flexibility for stock options, while releasing claims and reaffirming confidentiality and non-disparagement commitments.

Also effective April 1, 2026, the board appointed veteran pharma and biotech executive Mark H. Pavao as an independent Class III director to fill the vacancy, granting him options to purchase 10,000 shares under the company’s equity plan and standard non-employee director compensation. The board and management emphasized that Pavao’s three decades of commercialization experience, particularly in neuroscience, are expected to support Coya’s progression from a clinical-stage developer toward potential commercialization of COYA 302 and other neuroinflammation-focused therapies.

Average Trading Volume: 196,842

Technical Sentiment Signal: Sell

Current Market Cap: $95.71M

For a thorough assessment of COYA stock, go to TipRanks’ Stock Analysis page.